Additional file 1 of Triglyceride-glucose index is associated with hypertension incidence up to 13 years of follow-up in mexican adults

Supplementary Material 1: Figure S1: Flowchart of the study population. Table S1: Characteristics of participants in the Health Workers Cohort Study according to the TyG index categories defined by tertiles at baseline (n=1,113

Validation parameters of the analytical method for to quantify ifosfamide in DBS at 45% HTC.

<p>The intra-day variability with quality controls was performed in three consecutive days, data for days 1 to 3 are depicted as a, b and c, respectively. SD: Standard Deviation. CV: Coefficient Variation. N/R: Not required according to the guidelines. Amount claimed for QC1, QC2 and QC3 were 300, 4000 and 8000 ng/mL, respectively.</p><p>Validation parameters of the analytical method for to quantify ifosfamide in DBS at 45% HTC.</p

Chromatograms for multiple reaction monitoring (MRM) of individual channels.

<p>The figure shows Ifosfamide and cyclophosphamide on 24-h samples. Selectivity to other drugs administered with ifosfamide: vincristine, ondansetron, etoposide, carboplatin and methotrexate.</p

Influence of the haematocrit on ifosfamide blood determination.

<p>SD: Standard Deviation, % Deviation after triplicate quantification of a nominal concentration (5000 ng/mL) with a calibration curve constructed with 30% (A) and 45% (B) haematocrit, it was calculated as: (theoretical concentration minus calculated concentration/theoretical concentration)*100 [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0143421#pone.0143421.ref006" target="_blank">6</a>].</p><p>Influence of the haematocrit on ifosfamide blood determination.</p

Carryover effect on ifosfamide and cyclophosphamide.

<p>Panel A shows a blank sample chromatogram previously injected. Panel B shows the higher-limit at 10000 ng/mL concentration. Panels C and D show blank samples injected after the curve higher-limit. None of the blank samples showed carryover neither for ifosfamide nor for cyclophosphamide.</p

Validation parameters of the analytical method by UPLC-MS/MS, to quantify ifosfamide in DBS at 30% HTC.

<p>SD: Standard Deviation. CV: Coefficient of Variation. N/R: Not required according to the guidelines. Theoretical amounts for QC1, QC2 and QC3 were 300, 4000 and 8000 ng/mL, respectively.</p><p>Validation parameters of the analytical method by UPLC-MS/MS, to quantify ifosfamide in DBS at 30% HTC.</p

Comparison between medians for blood ifosfamide levels obtained from DBS.

<p>The figure shows a comparison between medians for blood ifosfamide levels obtained from DBS after 12 hours (dark gray box) and 24 hours (Light gray box), p <0.0001.</p

Health Workers Cohort Study: Methods and Study Design.

Self-administered questionnaires for "The Health Workers Cohort Study

Additional file 1: of Interaction between FTO rs9939609 and the Native American-origin ABCA1 rs9282541 affects BMI in the admixed Mexican population

Panels of ancestry informative markers used for each cohort [18]. (DOC 30 kb